RYC(SZ:003010) Changjiang Securities·2025-11-17 14:12Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - The company reported a revenue of 2.14 billion yuan for Q1-Q3 2025, representing a year-on-year growth of 85.3%. The net profit attributable to shareholders was 105 million yuan, up 81.6% year-on-year. In Q3 alone, revenue reached 820 million yuan, with a year-on-year increase of 123%, and net profit was 32.51 million yuan, growing 73% year-on-year [2][4]. Summary by Sections Financial Performance - For Q1-Q3 2025, the company achieved a revenue of 2.14 billion yuan, a year-on-year increase of 85.3%, and a net profit of 105 million yuan, up 81.6%. In Q3, revenue was 820 million yuan, reflecting a 123% year-on-year growth, while net profit was 32.51 million yuan, increasing by 73% [2][4]. Brand Performance - The self-owned brand and brand management segments showed significant growth, with revenues of 450 million yuan and 200 million yuan respectively in Q3, marking increases of 344.5% and 114.1% year-on-year. The self-owned brand "Zhanjia" continued its high growth trajectory, achieving Q3 revenue of 230 million yuan, up 118.9% year-on-year [6]. Profitability - The company's gross margin improved by 11.3 percentage points to 61% in Q3 2025, primarily due to the rapid growth of high-margin self-owned brand businesses. The expense ratios for sales, management, R&D, and finance increased by 17.7%, -4.1%, -0.4%, and 0.4 percentage points respectively [6]. Future Outlook - The company is expected to maintain strong growth in its self-owned brands, with projections for EPS of 0.58, 1.13, and 1.61 yuan per share for 2025-2027. The ongoing expansion in the health product sector and the successful launch of new products are anticipated to further enhance customer reach and profitability [6].